Maven Securities’s Relay Therapeutics RLAY Stock Holding History

Maven Securities’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-337,426	Closed	-$2.39M	–	992
2024 Q3	$2.39M	Buy	+337,426	New	+$2.52M	0.05%	318

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Maven Securities's RLAY Position: Q4 2024 in Review

Maven Securities sold out of Relay Therapeutics (RLAY) in Q4 2024, closing a stake of 337,426 shares — an estimated $2.39M sold.

Maven Securities first reported a position in RLAY in Q3 2024 and held it in 1 quarter. The position peaked at $2.39M in Q3 2024. 199 funds tracked by Wall St. Rank hold RLAY as of Q4 2024.

Maven Securities reported no remaining Relay Therapeutics position as of Q4 2024 after selling out during the quarter.
Maven Securities sold 337,426 Relay Therapeutics shares in Q4 2024, an estimated $2.39M.
Maven Securities first reported a position in Relay Therapeutics in Q3 2024 and held it in 1 quarter.
Maven Securities's Relay Therapeutics position peaked at $2.39M in Q3 2024.
199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2024.

Based on Maven Securities's 13F filing for Q4 2024, filed 14 Feb 2025.